ASEAN has become the most potential emerging market of Chinese pharmaceutical products and trade in service of Chinese medicine.The fully completed China ASEAN Free Trade Area will boost the bilateral medicine trade.Non-tariff barriers， instead of tariff will become the main obstacle to the medicine trade.The main obstacles to the development of trade in service of Chinese medicine are the legal status of Chinese medicine in the ASEAN countries， the qualification recognition of Chinese medicine service provider， rights of establishment and other aspects of the regulation， i.e.in two aspects of policy the domestic regulation and market access and the measures and implementation for the policy.Chinese medicine trade in service ask and offer negotiation should focus on the following aspects，such as further inclusion of Chinese medicine trade in service into China ASEAN trade in service gradually-liberalization agenda，the establishment of a national level China- ASEAN regulatory coordination and mutual recognition mechanism in medicine registration，cooperation and coordination in trade in service of Chinese medicine and in the Pharmacopoeia standards， policy consultation in market access and national treatment of trade in service of Chinese medicine， as well as in terms of horizontal commitment and specific commitments， so as to gradually improve the commitment level and promote the China ASEAN TCM trade in services gradual liberalization process.